ARCHIVES

NCI disclosure of walk-out by Data and Safety Monitoring Board of the National Lung Screening Trial may be harmful, improper, experts say.

This article is from The Cancer Letter archive.

Vol. 30 No. 16 | April 16, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Pretreatment Critical In Antimetic Therapy, Sallan Says; Aging/Cancer Symposium Planned

July 11, 1980

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005

In Brief: Transition Team Denies It Is Seeking New NCI Director; Garb Undergoes Surgery At M.D.A

November 28, 1980

Statistics Review Shows Improved Mortality Under 65, Through 1986

January 19, 1990

Phase III Trial Shows Benefit For Old Drugs, Old Device, For Ovarian Cancer, But Will Practice Change?

January 20, 2006

Conversation With The Cancer Letter: Wicha to Leave Director’s Job at UMich

November 8, 2013